表紙
市場調查報告書
商品編碼
1025469

全球先天性心臟病市場(2021-2027)

Congenital Heart Diseases Market 2021-2027

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在預測期內,全球先天性心臟病市場預計將以約 9.1% 的複合年增長率增長。先天性心臟病患病率上升導致市場擴張。此外,醫學進步,如持續的藥物發現、設備以及政府和非政府組織治療這些疾病的舉措,正在進一步推動市場增長。此外,新興國家的機會不斷擴大,例如先進醫療基礎設施的發展,預計將推動市場增長。

然而,治療先天性心臟病的高昂費用阻礙了市場的增長。在 COVID-19 大流行期間,全球先天性心臟病市場一直低迷,患者住院率大幅下降,只能提供緊急醫療和初級保健服務。這降低了診斷測試的可用性並影響了先天性心臟病設備的銷售。

市場根據缺陷類型、診斷、治療和最終用戶進行分類。根據缺損類型,市場分為心臟瓣膜缺損、心壁缺損和血管缺損。根據診斷,市場分為超聲心動圖、胸部 X 光、MRI 掃瞄等。根據治療,市場分為藥物治療、植入式心臟裝置、導管插入術、心臟直視手術和心臟移植。另外,根據最終用戶,它分為醫院/診所、診斷中心等。

本報告調查了全球先天性心臟病市場,概述了市場,分析了市場增長和障礙、市場機會、缺陷類型/診斷/治療/最終用戶/區域市場規模。它提供了系統信息,例如趨勢和預測、競爭條件以及主要公司的概況。

目錄

第 1 章報告概述

第 2 章市場概覽和洞察

  • 調查範圍
  • 分析師洞察和當前市場趨勢

第三章競爭形勢

  • 主要公司分析
  • 重要的戰略分析
  • COVID-19 對主要參與者的影響

第 4 章市場決定因素

  • 增長因素
  • 抑製器
  • 市場機會

第五章市場細分

  • 按缺陷類型
    • 心臟瓣膜缺損
    • 心壁缺損
    • 血管缺損
  • 通過診斷
    • 超聲心動圖
    • 胸部 X 光檢查
    • 核磁共振掃瞄
    • 其他
  • 通過治療
    • 藥物治療
    • 植入式心臟裝置
    • 導管治療
    • 心臟直視手術
    • 心臟移植
  • 最終用戶
    • 醫院和診所
    • 診斷中心
    • 其他

第六章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他領域

第七章公司簡介

  • Abbott Laboratories
  • AstraZeneca Plc
  • Becton Dickson & Co.
  • Bio-Rad Laboratories
  • Boston Scientific Corp.
  • Laboratory Corporation of America Holdings(LabCorp)
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Janssen Pharmaceuticals, Inc.
  • Medtronic
  • Viatris Inc.
  • Novartis Ag
  • Pfizer, Inc.
  • Randox Laboratories Ltd.
  • Response Biomedical Corporation
  • Sanofi S.A.
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Vericel Corporation
目錄
Product Code: OMR2023901

Full-title:Global Congenital Heart Diseases Market, By Defect Type (Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, By Diagnosis (Echocardiogram, Chest X-ray, MRI, Other), By Treatment (Medications, Implantable Heart Device, Catheter Procedures, Open Heart Surgery, Heart Transplant), End-Users (Hospitals and Clinics, Diagnostic Centers, Others) Forecast Period 2021-2027.

The global congenital heart diseases market is projected to grow at a CAGR of nearly 9.1% during the forecast period. The rise in the prevalence of congenital heart diseases is resulting in an increasing growth of the market. Furthermore, medical advancements that include ongoing drug discovery, devices, and government and non-government organizational initiatives to treat these diseases are further driving the market growth. Additionally, evolving opportunities in emerging economies such as the development of advanced healthcare infrastructure facilities are also expected to propel the growth of the market. 

However, the high costs associated with the treatment of congenital heart disease are hindering the growth of the market. The global congenital heart disease market suffered a downfall during the COVID-19 pandemic as the number of patient hospitalizations has decreased significantly, and only emergency and primary care services are available during COVID-19. Therefore, this has reduced the availability of diagnostic tests and impacted the sales of devices for congenital heart disease. 

The market is segmented based on defect type, diagnosis, treatment, and end-user. Based on the defect type, the market is segmented into heart valve defects, heart wall defects, blood vessel defects. Based on the diagnosis, the market is segmented into echocardiogram, chest x-ray, MRI scan, and others. Based on the treatment, the market is segmented into medications, implantable heart devices, catheter procedures, open-heart surgery, and heart transplant. Apart from this, by end-users, the market is segmented into hospitals and clinics, diagnostic centers, and others. 

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is anticipated to witness a significant share in the market due to increasing healthcare spending, technological advancement in early diagnosis of the disease, and increased population awareness about the diagnosis and treatment of these congenital heart diseases. Furthermore, increasing adoption of minimally invasive procedures and the presence of a large number of market players in the region is estimated to be the major factors that are backing the growth of the market.  Europe is regarded as the second-largest region for the market owing to increase awareness about the disease in the region. Whereas, Asia-Pacific is expected to be the fastest-growing region for the market. The attributable factors are improving healthcare infrastructure and rising medical tourism in the region. Moreover, there is a high prevalence of diabetes in densely populated countries such as India, China, and South Korea which is attributing to the growth of the market. 

Research Methodology

The market study of the global congenital heart diseases market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Congenital Heart Disease Market Research and Analysis by Defect Type
  • Global Congenital Heart Disease Market Research and Analysis by Diagnostics
  • Global Congenital Heart Disease Market Research and Analysis by Treatment
  • Global Congenital Heart Disease Market Research and Analysis by End-user

The Report Covers

  • Comprehensive research methodology of the global congenital heart disease market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global congenital heart disease market.
  • Insights about market determinants that are stimulating the global congenital heart disease market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Congenital Heart DiseaseIndustry
  • Recovery Scenario of Global Congenital Heart DiseaseIndustry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Congenital Heart Disease Market, By Defect Type
    • 5.1.1. Heart Valve Defects
    • 5.1.2. Heart Wall Defects
    • 5.1.3. Blood Vessel Defects
  • 5.2. Global Congenital Heart Disease Market, By Diagnosis
    • 5.2.1. Echocardiogram
    • 5.2.2. Chest X-Ray
    • 5.2.3. MRI Scan
    • 5.2.4. Others
  • 5.3. Global Congenital Heart Disease Market, By Treatment
    • 5.3.1. Medications
    • 5.3.2. Implantable Heart Devices
    • 5.3.3. Catheter Procedures
    • 5.3.4. Open Heart Surgery
    • 5.3.5. Heart Transplant
  • 5.4. Global Congenital Heart Disease Market, By End-User
    • 5.4.1. Hospitals and Clinics
    • 5.4.2. Diagnostic Centres
    • 5.4.3. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. AstraZeneca Plc
  • 7.3. Becton Dickson & Co.
  • 7.4. Bio-Rad Laboratories
  • 7.5. Boston Scientific Corp.
  • 7.6. Laboratory Corporation of America Holdings (LabCorp)
  • 7.7. F. Hoffmann-La Roche Ltd.
  • 7.8. Glaxosmithkline Plc
  • 7.9. Janssen Pharmaceuticals, Inc.
  • 7.10. Medtronic
  • 7.11. Viatris Inc.
  • 7.12. Novartis Ag
  • 7.13. Pfizer, Inc.
  • 7.14. Randox Laboratories Ltd.
  • 7.15. Response Biomedical Corporation
  • 7.16. Sanofi S.A.
  • 7.17. Siemens Healthineers
  • 7.18. Thermo Fisher Scientific Inc.
  • 7.19. Vericel Corporation

LIST OF TABLES

  • 1. GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 2. GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2020-2027($ MILLION)
  • 3. GLOBAL HEART VALVE DEFECTS INCONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 4. GLOBAL HEART WALL DEFECTSIN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 5. GLOBAL BLOOD VESSEL DEFECTS INCONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 6. GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
  • 7. GLOBAL ECHOCARDIOGRAM INCONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 8. GLOBAL CHEST X-RAY IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 9. GLOBAL MRI SCAN IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 10. GLOBAL OTHERS IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 11. GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 12. GLOBAL MEDICATIONS FOR CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 13. GLOBAL IMPLANTABLE HEART DEVICES FOR CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 14. GLOBAL CATHETER PROCEDURES FOR CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 15. GLOBAL OPEN-HEART SURGERY FOR CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 16. GLOBAL HEART TRANSPLANT FOR CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 17. GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 18. GLOBAL HOSPITALS AND CLINICS IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 19. GLOBAL DIAGNOSTIC CENTRES IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 20. GLOBAL OTHER IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 21. NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 22. NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2020-2027($ MILLION)
  • 23. NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
  • 24. NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 25. NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 26. EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 27. EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2020-2027($ MILLION)
  • 28. EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
  • 29. EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 30. EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 31. ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 32. ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2020-2027($ MILLION)
  • 33. ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
  • 34. ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 35. ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 36. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 37. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2020-2027($ MILLION)
  • 38. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
  • 39. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 40. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL CONGENITAL HEART DISEASE MARKET, 2020-2027($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL CONGENITAL HEART DISEASE MARKET BY SEGMENT, 2020-2027($ MILLION)
  • 3. RECOVERY OF GLOBAL CONGENITAL HEART DISEASE MARKET, 2021-2027(%)
  • 4. GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY DEFECT TYPE, 2020 VS 2027(%)
  • 5. GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY DIAGNOSIS, 2020 VS 2027(%)
  • 6. GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY TREATMENT, 2020 VS 2027(%)
  • 7. GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027(%)
  • 8. GLOBAL HEART VALVE DEFECTS INCONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 9. GLOBAL HEART WALL DEFECTSIN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 10. GLOBAL BLOOD VESSEL DEFECTS INCONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 11. GLOBAL ECHOCARDIOGRAM IN FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 12. GLOBAL CHEST X-RAY IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 13. GLOBAL MRI SCAN IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 14. GLOBAL OTHERS IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 15. GLOBAL MEDICATIONS FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 16. GLOBAL IMPLANTABLE HEART DEVICES FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 17. GLOBALCATHETER PROCEDURES FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 18. GLOBAL OPEN-HEART SURGERY FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 19. GLOBAL HEART TRANSPLANT FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 20. GLOBAL HOSPITALS AND CLINICS IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 21. GLOBAL DIAGNOSTIC CENTRES IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 22. GLOBAL OTHER IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 23. US CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 24. CANADA CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 25. UK CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 26. FRANCE CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 27. GERMANY CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 28. ITALY CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 29. SPAIN CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 30. REST OF EUROPE CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 31. INDIA CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 32. CHINA CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 33. JAPAN CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 34. SOUTH KOREA CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 35. REST OF ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 36. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)